A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Key facts

Sponsor

Oliver Blanchard

Principal Investigator

Oliver Blanchard, MD

McGill University - Montreal Neurological Institute

Intervention

Darifenacin 7.5 MG Extended Release Oral Tablet(drug)

Enrollment

30 enrolled

Eligibility

18-85 years · All sexes

Timeline

2024 – 2027

Study locations (2)

• Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
• Montreal Neurological Institute, Montreal, Quebec, Canada

Collaborators

Université de Montréal

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07401186
  Stimulation-Based Modulation of Spinal and Cortical Sensory Pathways
  Peter C. Gerszten, MD
• RECRUITINGNCT07467187
  Invasive Home Ventilation in Denmark
  Rigshospitalet, Denmark
• RECRUITINGNCT07502677
  Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis
  Royal Brompton & Harefield NHS Foundation Trust
• RECRUITINGNANCT07446114
  Functional Outcomes and Control Using Synchron BCI - Canada
  Synchron, Inc.
• ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806
  HEALEY ALS Platform Trial - Regimen I NUZ-001
  Merit E. Cudkowicz, MD
• ENROLLING BY INVITATIONNANCT07298486
  Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS
  Nova Southeastern University
• ACTIVE NOT RECRUITINGPHASE1NCT07204977
  Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
  National Institute of Neurological Disorders and Stroke (NINDS)
• RECRUITINGPHASE3NCT07322003
  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
  Prilenia

See all trials for Amyotrophic lateral sclerosis →